NCT07181681View on ClinicalTrials.gov

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

October 22, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
Solid TumorsAdvanced Solid Tumor
Interventions
DRUG

BG-C0902

Administered by intravenous infusion

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY